Guardant Health Gains Momentum with Dual Breakthroughs in Cancer Diagnostics

Guardant Health has received two significant boosts that could finally deliver the growth trajectory investors have been anticipating. After recent challenges with disappointing algorithm updates, the liquid biopsy specialist now has powerful new catalysts: a major commercial partnership and compelling clinical study results that strengthen the bull case for the company.

Fresh data presented at the World Conference on Lung Cancer demonstrated the critical role of Guardant’s Reveal test in detecting minimal residual disease following lung cancer surgeries. These Phase III NADIM ADJUVANT study results provide independent validation that extends the technology’s application well beyond colorectal cancer screening, potentially opening Read more...